Market Access/ News/ News/ News/ News/ Oncology/ Sales and Marketing Mirati challenges Amgen with FDA okay for KRAS drug Phil Taylor adagrasib, Amgen, KRAS, Krazati, Lumakras, Mirati, Oncology, regulatory approval 0 Comment Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati’s adagrasib as Share X Mirati challenges Amgen with FDA okay for KRAS drug https://pharmaphorum.com/news/mirati-challenges-amgen-with-fda-okay-for-kras-drug/
News/ News/ Oncology Mirati heads for FDA verdict on KRAS drug with new data Phil Taylor adagrasib, Amgen, asco, KRAS, Lumakras, Mirati, Non-small cell lung cancer 0 Comment Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete Share X Mirati heads for FDA verdict on KRAS drug with new data https://pharmaphorum.com/news/mirati-heads-for-fda-verdict-on-kras-drug-with-new-data/
adagrasib, Amgen, KRAS, Krazati, Lumakras, Mirati, Oncology, regulatory approval
0 Comment
